Lorus Therapeutics Inc. (LOR.TO) Thursday reported a third quarter loss which narrowed from last year, helped mainly by lower operating expenses.
Net loss for the period decreased to C$1.0 million or C$0.05 per share from C$1.5 million or C$0.10 per share last year.
Research and development expenses decreased to C$543 thousand from C$847 thousand last year. Salaries decreased to C$163 thousand from C$232 thousand last year due to reduction in headcount. As a result, operating expenses declined to C$ 1.02 million from C$1.55 million last year.
The Toronto-based bio-pharma company did not realize any revenues as all of its drug candidates are currently undergoing pre-clinical and clinical trials.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.